In:
Journal of Veterinary Internal Medicine, Wiley, Vol. 28, No. 2 ( 2014-03), p. 538-546
Abstract:
Canine T‐cell lymphoma ( TCL ) is conventionally considered an aggressive disease, but some forms are histologically and clinically indolent. CD 4 TCL is reported to be the most common subtype of TCL . We assessed flow cytometric characteristics, histologic features when available, and clinical outcomes of CD 4+ TCL to determine if flow cytometry can be used to subclassify this group of lymphomas. Objective To test the hypothesis that canine CD4+ T‐cell lymphoma ( TCL ) is a homogeneous group of lymphomas with an aggressive clinical course. Animals Sixty‐seven dogs diagnosed with CD 4+ TCL by flow cytometry and treated at 1 of 3 oncology referral clinics. Methods Retrospective multivariable analysis of outcome in canine CD 4+ TCL including patient characteristics, treatment, and flow cytometric features. Results The majority of CD 4+ TCL were CD 45+, expressed low class II MHC , and exhibited an aggressive clinical course independent of treatment regimen (median survival, 159 days). Histologically, CD 4+ TCL were classified as lymphoblastic or peripheral T cell. Size of the neoplastic lymphocytes had a modest effect on both PFI and survival in this group. A small number of CD 4+ TCL were CD 45− and class II MHC high, and exhibited an apparently more indolent clinical course (median survival not yet reached). Conclusions and Clinical Importance Although the majority of CD 4+ TCL in dogs had uniform clinical and flow cytometric features and an aggressive clinical course, a subset had a unique immunophenotype that predicts significantly longer survival. This finding strengthens the utility of flow cytometry to aid in the stratification of canine lymphoma.
Type of Medium:
Online Resource
ISSN:
0891-6640
,
1939-1676
DOI:
10.1111/jvim.2014.28.issue-2
Language:
English
Publisher:
Wiley
Publication Date:
2014
detail.hit.zdb_id:
2177690-8
SSG:
22
Permalink